Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Regulatory Affairs Reorg To Include Inspectors Trained In Real-World Evidence, Califf Says

Executive Summary

The US FDA Commissioner acknowledged that the inspectorate has not been prepared for RWE, but as part of the revamp, a dedicated team will encourage its use “when it’s appropriate.”

You may also be interested in...



US FDA’s New Regulatory Affairs Head Should Be ‘Highly Technically Competent’ But ‘Splendid On The Human Side,’ Califf Says

Agency has seen ‘a good slate of applicants’ for the post of associate commissioner for regulatory affairs, who will oversee a revamped field organization focused on inspections, investigations and imports. New update to the reorg plans calls for medical product and specialty labs to be moved out of the Office of Regulatory Affairs and relocated to the Office of the Chief Scientist.

US FDA’s Office Of Regulatory Affairs To Focus On Investigations, Inspections And Imports

ORA to shed more responsibilities as the FDA focuses the likely-to-be renamed field organization more on inspections while revamping the agency's Human Food Program.

US FDA Oncology Diagnostics Pilot Is ‘Interim Step’ To Fill VALID Void, But ‘Stuck In Neutral’

Without sponsors willing to work with them and in the absence of legislation giving FDA authority over lab-developed tests, the agency has launched internal programs to both gain more oversight – and spur innovation.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT148377

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel